243 related articles for article (PubMed ID: 32028750)
1. [Renal Cancer Tissue after Nivolumab/Ipilimumab Combination Therapy for Metastatic Renal Cell Carcinoma].
Okuno Y; Tanaka R; Mikami K; Takeuchi T
Hinyokika Kiyo; 2020 Jan; 66(1):13-17. PubMed ID: 32028750
[TBL] [Abstract][Full Text] [Related]
2. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
George G; Schmidt L; Tolat P; Riese M; Kilari D
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501
[TBL] [Abstract][Full Text] [Related]
3. BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.
Epaillard N; Simonaggio A; Elaidi R; Azzouz F; Braychenko E; Thibault C; Sun CM; Moreira M; Oudard S; Vano YA
Bull Cancer; 2020 Jun; 107(5S):eS22-eS27. PubMed ID: 32620212
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
5. Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma.
Hashimoto M; Nakayama T; Fujimoto S; Inoguchi S; Nishimoto M; Kikuchi T; Adomi S; Banno E; De Velasco MA; Saito Y; Shimizu N; Mori Y; Minami T; Fujita K; Nozawa M; Nose K; Yoshimura K; Uemura H
Anticancer Drugs; 2022 Jan; 33(1):e818-e821. PubMed ID: 34486537
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma.
Kikuchi H; Osawa T; Matsumoto R; Abe T; Maruyama S; Harabayashi T; Miyata H; Kashiwagi A; Ikeshiro S; Sazawa A; Fukui R; Morita K; Takeuchi I; Hori K; Yamashita N; Minami K; Mochizuki T; Murai S; Shinohara N
Urol Oncol; 2022 Jan; 40(1):13.e19-13.e27. PubMed ID: 34716079
[TBL] [Abstract][Full Text] [Related]
7. [Deep and Durable Response After Discontinuation of Nivolumab/Ipilimumab Combination Therapy for Metastatic Renal Cell Carcinoma : A Case Report].
Tsuruta M; Shibasaki N; Iguch R; Yamaguchi T; Ota H; Fuchigami Y; Magaribuchi T; Naito H; Terai A
Hinyokika Kiyo; 2020 Dec; 66(12):443-448. PubMed ID: 33435655
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Pappilary Renal Cell Caircinoma which Responded Well to the Combination Therapy of Ipilimumab and Nivolumab --A CASE REPORT-].
Fukatani Y; Daizumoto K; Kadoriku F; Yamamoto H; Sasaki Y; Ozaki K; Ueno Y; Tuda M; Kusuhara Y; Fukawa T; Yamamoto Y; Yamaguchi K; Takahashi M; Kanayama H; Niki M; Uehara H
Hinyokika Kiyo; 2022 Apr; 68(4):107-111. PubMed ID: 35613898
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Nivolumab Plus Ipilimumab in a Patient With Renal Cell Carcinoma Concomitant With Cardiac Metastasis: A Case Report.
Shirotake S; Umezawa Y; Okabe T; Kaneko GO; Kanao K; Nishimoto K; Oyama M
In Vivo; 2020; 34(3):1475-1480. PubMed ID: 32354949
[TBL] [Abstract][Full Text] [Related]
10. Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis.
Yang Y; Mori SV; Li M; Hinkley M; Parikh AB; Collier KA; Miah A; Yin M
Cancer Med; 2022 Apr; 11(7):1669-1677. PubMed ID: 35138046
[TBL] [Abstract][Full Text] [Related]
11. Two cases of nivolumab plus ipilimumab therapy for dialysis patients with advanced bone metastasis from renal cell carcinoma.
Takahashi M; Takishita M; Yamazato Y; Kakinoki H; Udo K; Tobu S; Noguchi M
CEN Case Rep; 2023 May; 12(2):237-241. PubMed ID: 36402939
[TBL] [Abstract][Full Text] [Related]
12. [Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma].
Oya M; Tajima Y; Kabu K
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1397-1404. PubMed ID: 31530779
[TBL] [Abstract][Full Text] [Related]
13. Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy.
Carril-Ajuria L; Lora D; Carretero-González A; Martín-Soberón M; Rioja-Viera P; Castellano D; de Velasco G
Clin Genitourin Cancer; 2021 Apr; 19(2):95-102. PubMed ID: 33189597
[TBL] [Abstract][Full Text] [Related]
14. Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinoma.
Kubo T; Sugawara T; Shinkawa T; Kurisu T; Kouzen N; Tanaka T; Fukuta F; Yamasaki K; Sugita S; Matsuo K; Morita R; Hirohashi Y; Tsukahara T; Kanaseki T; Hasegawa T; Masumori N; Torigoe T
Immunol Med; 2021 Jun; 44(2):136-141. PubMed ID: 32634346
[TBL] [Abstract][Full Text] [Related]
15. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.
Albiges L; Powles T; Staehler M; Bensalah K; Giles RH; Hora M; Kuczyk MA; Lam TB; Ljungberg B; Marconi L; Merseburger AS; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Bex A
Eur Urol; 2019 Aug; 76(2):151-156. PubMed ID: 31151678
[TBL] [Abstract][Full Text] [Related]
16. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
Kido K; Hatakeyama S; Numakura K; Tanaka T; Oikawa M; Noro D; Hosogoe S; Narita S; Inoue T; Yoneyama T; Ito H; Nishimura S; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
Int J Clin Oncol; 2021 Jan; 26(1):154-162. PubMed ID: 33067647
[TBL] [Abstract][Full Text] [Related]
17. Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation.
Schvartsman G; Carneiro APCD; Filippi RZ; Rao P; Msaouel P
Clin Genitourin Cancer; 2019 Aug; 17(4):315-318. PubMed ID: 31213412
[No Abstract] [Full Text] [Related]
18. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
19. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
20. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis.
Shaw LK; Wiele AJ; Sircar K; Wood CG; Msaouel P
Cancer Treat Res Commun; 2021; 27():100349. PubMed ID: 33725559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
